Beijing Beikehuaxia Bio-medical Technology Co., Ltd.

Guangzhou Liushun Biotechnology Co., Ltd.

Lianwu Deng

Yan Wang

Jin Ma

Bing Liu

Shuang Xie

Nengan Chen

Xueqi Qian

Jingsi Dai

Xihong Liu

Junjun Dong

Daping Li

A multi-target kinase inhibitor is shown in formula (I), in which R is selected from formula (a), formula (b), formula (c), formula (d), formula (e) and formula (f). The multi-target kinase inhibitor can effectively inhibit the enzymatic activities of RET, VEGFR3 and PDGFRA, and can effectively treat diseases that are regulated and controlled by multi-target kinases and are related to abnormal signal transduction pathways of the multi-target kinases, including cancers of breast, respiratory tract, brain, reproductive organ, digestive tract, urinary tract, eye, liver, skin, head and/or neck and distant metastatic cancers thereof, and lymphoma, sarcoma, leukemia and the like. The active ingredients of the pharmaceutical composition of the present invention comprise a multi-target kinase inhibitor, which accounts for 1-50 wt % of the composition.

Multi-target kinase inhibitor, pharmaceutical composition, and preparation method for multi-target kinase inhibitor and use thereof

Growing community of inventors

Guangdong, China

Lianwu Deng